Clinical trial · Interventional
Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients
A Comparison Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients Who Receive Chemotherapy, Multicenter Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to Primary Objectives: 1. To compare the incidence of febrile neutropenia in patients with non-Hodgkin's lymphoma who received early or late granulocyte colony-stimulating factor (G-CSF) during standard chemotherapy in a multicenter study 2. To determine the incidence of leukopenia and neutropenia in patients with non-Hodgkin's lymphoma who received early or late G-CSF during standard chemotherapy in a multicenter study Secondary Objectives: 1. To determine changes in white blood cell, hemoglobin, and platelet levels in patients with non-Hodgkin's lymphoma who received early or late G-CSF during standard chemotherapy. 2. To determine the quality of life of patients with non-Hodgkin's lymphoma who undergoing standard chemotherapy and with neutropenia Researchers will compare the outcome between patients received either early G-CSF (within 72 hours) or late G-CSF (after 72 hours). All patients will be followed up to monitor for febrile neutropenia events, other hematological parameters and quality of life.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Febrile Neutropenia (FN) | — | UNRESOLVED | — |
| Granulocyte Colony Stimulating Factor | — | UNRESOLVED | — |
| Myelosuppression Adult | — | UNRESOLVED | — |
| Non-Hodgkin's Lymphoma (NHL) | Non-Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Early receiving G-CSF group | Drug | — | UNRESOLVED |
| Late receiving G-CSF group | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Early receiving G-CSF group
- description
- Early receiving G-CSF group Patients in early receiving G-CSF group accept within 72 hours post chemotherapy
- interventionNames
- Drug: Early receiving G-CSF group
- type
- PLACEBO_COMPARATOR
- label
- Late receiving G-CSF group
- description
- Last receiving G-CSF group Patients in early receiving G-CSF group accept after 72 hours post chemotherapy
- interventionNames
- Drug: Late receiving G-CSF group
Primary outcomes (2)
- measure
- Incidence of febrile neutropenia
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Aged 18 years or old * Confirmed lymphoma undergoing standard chemotherapy * Signed an approval informed consent * Has a good understanding of Thai * Available for follow-up after chemotherapy Exclusion Criteria: * Pregnancy or lactation * Serious concomitant diseases and discontinuous treatment such as cardiovascular, liver, or kidney diseases * Contraindication to chemotherapy or G-CSF administration * Antibiotic use within 1 week prior to enrollment
References
Publications (0)
Data not yet available